Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 10370-0268
What Is the Drug Identified by NDC 10370-0268?
NDC 10370-0268 corresponds to Aflibercept Injection, 40 mg/mL, marketed as EYLEA. It is indicated for the treatment of several ocular neovascular conditions, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and central retinal vein occlusion (CRVO).
Market Size and Demand Drivers
Indications and Prevalence
- AMD affects approximately 11 million Americans aged 50 and older.
- Diabetic retinopathy affects over 21 million adults in the U.S.
- CRVO occurrences are estimated at 0.8-1.2 per 1,000 people annually.
Total market estimate for ocular conditions treatable with aflibercept exceeds $4.5 billion annually in the U.S. alone, considering multiple indications.
Key Market Players
- Regeneron Pharmaceuticals (EYLEA)
- Bayer AG (in partnership with Regeneron in some regions)
- Roche (lucentis competing product)
Penetration and Market Share
- EYLEA holds approximately 70% of the anti-VEGF market in ophthalmology in the U.S.
- The drug's effective dosing interval (monthly or bimonthly) supports high patient adherence.
Current Pricing Landscape
U.S. List Price
- The average wholesale price (AWP) for EYLEA is approximately $1,950 per vial.
- Treatment typically involves 2 mg injections administered every 4-8 weeks, with a median of 8–12 injections per year.
Reimbursement and Net Price
- Commercial insurers negotiate discounts, reducing net prices by 15-30%.
- Medicaid and Medicare have specific reimbursement formulas, generally resulting in net prices around $1,300 a dose.
Price Trends and Projections
Historical Pricing Trends (2018–2022)
- The AWP of EYLEA has increased at an annual rate of about 3-4%, driven by inflation and slight adjustments in dosing protocols.
- Market trends show high stability, with minimal impact from biosimilar competition due to patent exclusivity.
Future Price Outlook (2023–2028)
- Patent protection is expected to extend until 2028, delaying biosimilar incursions.
- Price stabilization or slight decrease (around 1-2% annually) is anticipated with increasing rebates and discounting practices.
- Price convergence in the biosimilar segment is unlikely until patent expiry, but R&D progresses for biosimilars in other regions.
Competitive Landscape and Biosimilar Development
- Biosimilar candidates are in development in Europe and Asia, with some expected FDA submissions around 2025.
- Biosimilar entry could lead to a 20-30% price reduction but remains distant until patent expiration.
Policy and Regulatory Impact
- The U.S. Inflation Reduction Act and value-based contracting may influence net prices, encouraging manufacturers to offer rebates.
- Price regulation remains limited; the market largely relies on negotiated discounts and rebates.
Implications for Stakeholders
- Pharmaceutical companies will maintain high pricing until biosimilar approval and patent expiration.
- Healthcare providers will see stable demand due to the drug’s efficacy and dosing convenience.
- Payers will seek more aggressive rebate strategies to control costs as biosimilar competition approaches.
Key Takeaways
- The current U.S. wholesale price for EYLEA is approximately $1,950 per vial.
- Market demand remains strong driven by high prevalence of target conditions.
- Price inflation has been modest in recent years; slight reductions expected in the long term with biosimilar entry.
- Patent protections and regulatory delays sustain high prices until around 2028.
- Rebate negotiations and healthcare policy developments will influence net prices.
FAQs
1. When will biosimilars for aflibercept likely enter the U.S. market?
Biosimilars could gain approval and market entry around 2025–2028, coinciding with patent expiry.
2. How much could biosimilars reduce the price of EYLEA?
Biosimilar competition is projected to lower prices by approximately 20–30%.
3. What is the standard dosing regimen for EYLEA?
Typically, 2 mg administered monthly for the first few months, then every 8 weeks.
4. Are there significant differences in pricing between different regions?
Yes, European markets often have lower prices due to price regulation, with discounts of up to 40%.
5. How do rebates impact the net price paid by payers?
Rebates can reduce net prices by 15–30%, depending on contracts and payer negotiations.
References
- IQVIA, "The Market for Ophthalmic Drugs," 2022.
- FDA Approval Documents, "EYLEA (Aflibercept) NDA," 2011.
- SSR Health, "U.S. Pharmaceutical Pricing Trends," 2022.
- MedPage Today, "Biosimilar Outlook in Ophthalmology," 2023.
- CMS, "Medicare Part B Drug Reimbursement," 2022.
